Next Article in Journal
Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet
Next Article in Special Issue
The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS)
Previous Article in Journal
Genetic Diversity of Pinus nigra Arn. Populations in Southern Spain and Northern Morocco Revealed By Inter-Simple Sequence Repeat Profiles
Int. J. Mol. Sci. 2012, 13(5), 5659-5673; doi:10.3390/ijms13055659
Article

Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study

1,2,* , 2
,
1
,
1
,
1
,
1
,
1
,
1
 and
2
1 Buffalo Neuroimaging Analysis Center, State University of New York, Buffalo, NY 14203, USA 2 The Jacobs Neurological Institute, Department of Neurology, University at Buffalo, State University of New York, Buffalo, NY 14203, USA
* Author to whom correspondence should be addressed.
Received: 22 March 2012 / Revised: 23 April 2012 / Accepted: 3 May 2012 / Published: 10 May 2012
(This article belongs to the Special Issue Recent Advances in the Research of Multiple Sclerosis)
View Full-Text   |   Download PDF [242 KB, uploaded 19 June 2014]   |  

Abstract

This study explored the effect of glatiramer acetate (GA, 20 mg) on lesion activity using the 1.5 T standard MRI protocol (single dose gadolinium [Gd] and 5-min delay) or optimized 3 T protocol (triple dose of Gd, 20-min delay and application of an off-resonance saturated magnetization transfer pulse). A 15-month, phase IV, open-label, single-blinded, prospective, observational study included 12 patients with relapsing-remitting multiple sclerosis who underwent serial MRI scans (Days −45, −20, 0; the minus ign indicates the number of days before GA treatment; and on Days 30, 60, 90, 120, 150, 180, 270 and 360 during GA treatment) on 1.5 T and 3 T protocols. Cumulative number and volume of Gd enhancing (Gd-E) and T2 lesions were calculated. At Days −45 and 0, there were higher number (p < 0.01) and volume (p < 0.05) of Gd-E lesions on 3 T optimized compared to 1.5 T standard protocol. However, at 180 and 360 days of the study, no significant differences in total and cumulative number of new Gd-E and T 2 lesions were found between the two protocols. Compared to pre-treatment period, at Days 180 and 360 a significantly greater decrease in the cumulative number of Gd-E lesions (p = 0.03 and 0.021, respectively) was found using the 3 T vs. the 1.5 T protocol (p = NS for both time points). This MRI mechanistic study suggests that GA may exert a greater effect on decreasing lesion activity as measured on 3 T optimized compared to 1.5 T standard protocol.
Keywords: glatiramer acetate; gadolinium-enhancing lesions; magnetic resonance imaging; 1.5 T; 3 T; T2 lesions; pilot trial glatiramer acetate; gadolinium-enhancing lesions; magnetic resonance imaging; 1.5 T; 3 T; T2 lesions; pilot trial
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Zivadinov, R.; Hojnacki, D.; Hussein, S.; Bergsland, N.; Carl, E.; Durfee, J.; Dwyer, M.G.; Kennedy, C.; Weinstock-Guttman, B. Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. Int. J. Mol. Sci. 2012, 13, 5659-5673.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert